Rachel L Henson Selected Research

Amyloid (Amyloid Fibrils)

2/2024	Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset.
1/2024	Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer's disease.
10/2023	Diagnostic Utility of Cerebrospinal Fluid Biomarkers in Patients with Rapidly Progressive Dementia.
1/2023	Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40.
1/2023	Comparison of amyloid burden in individuals with Down syndrome versus autosomal dominant Alzheimer's disease: a cross-sectional study.
1/2023	CSF tau phosphorylation occupancies at T217 and T205 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease.
11/2022	Comparison of plasma and CSF biomarkers in predicting cognitive decline.
1/2022	Effect of Race on Prediction of Brain Amyloidosis by Plasma Aβ42/Aβ40, Phosphorylated Tau, and Neurofilament Light.
1/2021	Comparison of CSF biomarkers in Down syndrome and autosomal dominant Alzheimer's disease: a cross-sectional study.
1/2021	Clinical and Paraclinical Measures Associated with Outcome in Cerebral Amyloid Angiopathy with Related Inflammation.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rachel L Henson Research Topics

Disease

16	Alzheimer Disease (Alzheimer's Disease) 04/2024 - 01/2019
6	Cognitive Dysfunction 04/2024 - 01/2020
5	Neuroinflammatory Diseases 10/2023 - 01/2019
4	Inflammation (Inflammations) 01/2024 - 01/2020
3	Down Syndrome (Down's Syndrome) 01/2023 - 01/2020
2	Dementia (Dementias) 10/2023 - 01/2021
1	Amyloid Plaque 02/2024
1	Chronic Disease (Chronic Diseases) 11/2023
1	Neurodegenerative Diseases (Neurodegenerative Disease) 10/2023
1	Amyloidosis 01/2022
1	Gliosis 01/2021
1	Cerebral Amyloid Angiopathy (Congophilic Angiopathy) 01/2021
1	Disease Progression 01/2021
1	Autoimmune Diseases of the Nervous System 01/2021
1	Leukocytosis (Pleocytosis) 01/2021
1	Trisomy (Trisomies) 01/2021
1	Tauopathies 01/2020

Drug/Important Bio-Agent (IBA)

16	Biomarkers (Surrogate Marker)IBA 04/2024 - 01/2019
12	Amyloid (Amyloid Fibrils)IBA 02/2024 - 01/2019
5	NeurograninIBA 10/2023 - 01/2019
4	Proteins (Proteins, Gene)FDA Link 10/2023 - 01/2020
4	NeurocalcinIBA 10/2023 - 01/2019
3	Chitinase-3-Like Protein 1IBA 01/2021 - 01/2019
3	Synaptosomal-Associated Protein 25IBA 01/2021 - 01/2020
2	Amyloid beta-PeptidesIBA 01/2024 - 01/2020
2	Peptides (Polypeptides)IBA 01/2023 - 11/2022
1	ChitinasesIBA 10/2023
1	Glial Fibrillary Acidic ProteinIBA 10/2023
1	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 10/2023
1	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 01/2021
1	Methylprednisolone FDA LinkGeneric 01/2021
1	methylamphotericin B (AME)IBA 01/2021
1	Threonine (L-Threonine)FDA Link 01/2021
1	AcidsIBA 01/2020
1	Oxidants (Oxidizing Agents)IBA 01/2020
1	alpha-SynucleinIBA 01/2020
1	Nitric Oxide (Nitrogen Monoxide)FDA Link 01/2020

Therapy/Procedure

1	Therapeutics 02/2024